CN1541687A - A kind of Chinese patent medicine for treating diabetes - Google Patents
A kind of Chinese patent medicine for treating diabetes Download PDFInfo
- Publication number
- CN1541687A CN1541687A CNA2003101069542A CN200310106954A CN1541687A CN 1541687 A CN1541687 A CN 1541687A CN A2003101069542 A CNA2003101069542 A CN A2003101069542A CN 200310106954 A CN200310106954 A CN 200310106954A CN 1541687 A CN1541687 A CN 1541687A
- Authority
- CN
- China
- Prior art keywords
- chinese patent
- blood
- patent medicine
- water
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229960004756 ethanol Drugs 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 238000005202 decontamination Methods 0.000 claims description 6
- 230000003588 decontaminative effect Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000013583 drug formulation Substances 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 35
- 239000008280 blood Substances 0.000 abstract description 35
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 18
- 102000004877 Insulin Human genes 0.000 abstract description 9
- 108090001061 Insulin Proteins 0.000 abstract description 9
- 229940125396 insulin Drugs 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 210000002966 serum Anatomy 0.000 abstract description 8
- 230000037396 body weight Effects 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000003914 insulin secretion Effects 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 abstract 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 201000005665 thrombophilia Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 22
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical group C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000003390 Chinese drug Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000008517 radix Trichosanthis Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗糖尿病的中药，目的在于提供一种组方合理、具有降血糖，降血脂，改善血液高凝状态，降低外周血清胰岛素水平，缓解糖尿病并发症作用的中成药。本发明按重量百分比由下列组分组成：桑叶26～49％，荷叶16～48％，丹参25～42％。其有益效果是依据中医理论拟定辛润清热、升清降浊、活血化瘀治法，针对糖尿病及其并发症的主要病理环节，促进内源胰岛素分泌，促进糖代谢，控制体重，使血糖、血脂降低，降低血液粘度，促进微循环，从而治疗糖尿病及其并发症。The invention relates to a traditional Chinese medicine for treating diabetes, and aims to provide a Chinese patent medicine with reasonable formula, lowering blood sugar and blood fat, improving blood hypercoagulability, lowering peripheral serum insulin level, and alleviating diabetic complications. The invention is composed of the following components according to weight percentage: 26-49% of mulberry leaves, 16-48% of lotus leaves and 25-42% of salvia miltiorrhiza. Its beneficial effects are based on the theory of traditional Chinese medicine to formulate Xinrun clearing heat, promoting clearness and reducing turbidity, promoting blood circulation and removing blood stasis, aiming at the main pathological links of diabetes and its complications, promoting endogenous insulin secretion, promoting glucose metabolism, controlling body weight, making blood sugar, Reduce blood lipids, reduce blood viscosity, promote microcirculation, thereby treating diabetes and its complications.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of diabetes, specifically is the Chinese patent medicine of feedstock production with the natural drug.
Background technology
In recent years, along with China's rapid economy development, the raising of people's living standard, the sickness rate of type ii diabetes is more preceding obviously to be increased.Nineteen ninety-five whole nation Epidemiological study shows that the sickness rate of type ii diabetes has reached about 3%, is higher than type i diabetes far away, accounts for more than 90% of diabetes sum, has now become one of commonly encountered diseases of serious threat China people ' s health.Type ii diabetes does not still have the way of radical cure at present, and complication such as cardiovascular and cerebrovascular disease, renal failure and retinopathy usually occur to the later stage, and wherein hyperlipemia, blood high viscosity syndrome are most common complication.Overwhelming majority type ii diabetes patient need take hypoglycemic medicine throughout one's life, and clinical orally-taken blood sugar reducing drug main commonly used will have sulphanylureas, biguanides, non-sulphanylureas insulin succagoga, euglycemic agent and α glycosidase inhibitor at present.Clinical practice shows that there is certain individual variation in the patient for the blood sugar lowering curative effect of these medicines, and part patient exists constitutional to lose efficacy and secondary failure to sulfonylureas drugs for diabetes.In addition, also there are some side reactions in the part patient to oral antidiabetic drug.
The Chinese medicine diabetes have history of more than one thousand years, the Chinese patent medicine that some treatment diabetes are also arranged simultaneously, and compatibility adopts Chinese medicines such as QI invigorating, spleen invigorating, the kidney invigorating, heat clearing away more, medicine as treatment diabetes in the patent documentation adopts raw materials such as the Radix Astragali, Radix Scutellariae, Fructus Perillae, Radix Codonopsis, Radix Et Rhizoma Rhei, Radix Rehmanniae, Radix Bupleuri, Radix Salviae Miltiorrhizae, Radix Curcumae, Radix Trichosanthis, Gypsum Fibrosum, Semen Plantaginis, Rhizoma Dioscoreae, Fructus Schisandrae Chinensis to make (number of patent application: 02110059.4); With the Rhizoma Anemarrhenae, Radix Trichosanthis, Radix Panacis Quinquefolii, Radix Salviae Miltiorrhizae, Radix Et Rhizoma Rhei, Radix Notoginseng, Fructus Crataegi is that Main Ingredients and Appearance is made (number of patent application: 02104040.0).Both at home and abroad the hypoglycemic activity of effective ingredient, single medicinal material and the Chinese medicine compound of natural drug has also been done big quantity research, as: using Rhizoma Coptidis, Cortex Phellodendri and Radix Berberidis total alkaloids to be expected to develop becomes the medicine (number of patent application: 03111502.0) of diseases such as preparation treatment diabetes, blood fat reducing; Adopting the single medicinal material Cortex Mori by extracting its active component---the medicament of Cortex Mori polysaccharide preparation can be used for reducing post-prandial glycemia; Another kind is the medicament that is extracted the dried cream preparation of gained by Cortex Mori and Radix Salviae Miltiorrhizae, can be used for reducing post-prandial glycemia and while blood circulation promoting and blood stasis dispelling, blood circulation promoting helps generation, the development of delaying complications of diabetes and reduces the infringement (number of patent application: 02126798.7) of complication to the patient.Someone confirms that Folium Mori can reach blood sugar reducing function (" Chinese silkworm industry ", 2003.5) by suppressing the α glycosidase.
But existing medicine or prescription is numerous and jumbled, compatibility is unreasonable, or effect is too single, many target spots advantage of failing to embody Chinese medicine, effect is not very good, and the patient still has to depend on some Western medicine, as insulin.Therefore selection science, rationally and truly have the Chinese prescription of curative effect treatment diabetes extremely important concerning extensive patients.
Summary of the invention
The object of the present invention is to provide a kind of reasonable recipe, have blood sugar lowering, blood fat reducing improves high blood coagulation state, reduces the periphery serum insulin levels, controlling body weight, the Chinese patent medicine of minimizing, the effect of diabetes-alleviating complication.
The understanding that solution of the present invention is changeed diabetes pathology machine based on motherland's medical science, with reference to the modern pharmacological research achievement, draft the heat clearing away of hot profit, ascending the clear and descending the turbid, blood circulation promoting and blood stasis dispelling method of treatment according to theory of Chinese medical science, select the Folium Mori of hot profit heat clearing away, the Radix Salviae Miltiorrhizae of blood circulation promoting and blood stasis dispelling, the Folium Nelumbinis prescription of ascending the clear and descending the turbid, compatibility is reasonable, main pathology link at diabetes and complication thereof, promote endogenous insulin secretion, promote carbohydrate metabolism, controlling body weight makes blood glucose, blood fat reduce blood viscosity lowering, promote microcirculation, thus treatment diabetes and complication thereof.
The present invention is achieved by the following technical programs.
Chinese patent medicine of the present invention is to be made up of following component by weight percentage:
Folium Mori 26～49%, Folium Nelumbinis 16～48%, Radix Salviae Miltiorrhizae 25～42%, more than the consumption sum of each component be 100%.
Chinese patent medicine of the present invention, each components contents is preferably:
Folium Mori 32～40%, Folium Nelumbinis 24～32%, Radix Salviae Miltiorrhizae 28～36%.
Chinese patent medicine of the present invention, the best proportioning of each component is:
Folium Mori 38.5%, Folium Nelumbinis 30.8%, Radix Salviae Miltiorrhizae 30.7%.
The preparation method of Chinese patent medicine preparation of the present invention is:
(1), Folium Mori are soaked, adopt ultrasonic extraction method and its liquid is concentrated, the centrifugal precipitation of removing, supernatant is walked post, is washed till eluent with distilled water and adds till ethanol do not have a precipitation, eluent is concentrated, filtrate adds ethanol after concentrating again, leaves standstill the back sucking filtration, and precipitation is respectively washed for several times with dehydrated alcohol, acetone, drying obtains Folium Mori extract.
(2), Folium Nelumbinis is cut into filament, adding ethanol or sour water soaks, adopt heating reflux method to extract its concentrated solution, ethanol extract is admixed suitable resin, volatilizes ethanol, resin is added on the macroporous adsorptive resins, acid water extracting liquid is direct upper prop after the sodium hydroxide solution modulation, washes decontamination with water, reuse ethanol-water elution, decompression recycling ethanol, volatilize Folium Nelumbinis extract.
(3), Radix Salviae Miltiorrhizae chopping, boiling water boils to be carried, extracting solution washes decontamination through concentrating after-filtration with water by macroporous resin adsorption, water-ethanol-water elution again, the reclaim under reduced pressure eluent, drying, Radix Salviae Miltiorrhizae extract.
(4), get three kinds of extracts of above-mentioned Folium Mori, Folium Nelumbinis, Radix Salviae Miltiorrhizae and mix after routinely drug formulation process make Chinese patent medicine of the present invention.
Chinese patent medicine preparation of the present invention can be a said preparation on any pharmaceutics.
Characteristics of the present invention are to draft the heat clearing away of hot profit, ascending the clear and descending the turbid, blood circulation promoting and blood stasis dispelling method of treatment, treat at the main pathology link of diabetes and complication thereof, have overcome deficiencies such as existing medicament composing prescription is numerous and jumbled, effect is single, curative effect is not very good.
Further illustrate beneficial effect of the present invention by following zoopery.
Experimental example 1. the present invention are to the influence of normal mouse blood sugar
Get 30 of mices, male and female half and half, body weight 18～22g.Be divided into 3 groups at random, i.e. normal group, Chinese patent medicine group of the present invention and glipizide group.The morning every day gastric infusion, continuous 14d, fasting is 3 hours after the last administration, gets blood from the mouse orbit vein, surveys blood glucose.The result shows that Chinese patent medicine of the present invention obviously influences the nothing of normal mouse blood sugar.
Experimental example 2. the present invention are to the influence of the close pyridine diabetic mice of four oxygen
Get 10 of normal mouses, survey its blood glucose value, conventional feed is fed then.Get into the mould mice again and be divided into 3 groups at random, be i.e. model group, Chinese patent medicine group of the present invention and glipizide group, successive administration 14d.After the last administration 1 hour, with above 4 groups of mices, eye socket was got blood, surveys its blood glucose value.The result shows that Chinese patent medicine of the present invention can make the alloxan diabetes mouse blood sugar reduce (P＜0.05), sees Table 1.
The influence of the table 1. pair close pyridine blood glucose in diabetic mice of four oxygen
After the group Mus is counted the preceding administration of administration
Blood glucose (mmol/L)
Normal group 10 6.82 ± 2.61 6.36 ± 1.25
Model group 9 16.14 ± 3.32
* *11.88 ± 3.20
* *
Chinese drug-treated group 9 15.01 ± 3.73
* *8.24 ± 1.69
* △
Glipizide group 8 14.37 ± 4.41
* *5.27 ± 2.66
△ △ △
Annotate: compare with normal group,
*P＜0.05,
* *P＜0.001; Compare with model group,
△P＜0.05,
△ △ △＜0.001
3. pairs of streptozotocin mycin diabetes rat influences of experimental example
The method that adopts streptozotocin mycin (STZ) intravenous injection (30mg/kg) and give high caloric diet is duplicated type ii diabetes rat model (NIDDM), treated for 4 weeks respectively with Chinese patent medicine of the present invention, glipizide, measure body weight, serum insulin, serum levels of triglyceride, cholesterol, hemorheology and glucose tolerance test.
The result shows, Chinese patent medicine of the present invention has good improving carbohydrate tolerance, blood fat reducing, reduction blood viscosity, stop the generation of obesity and reduce the periphery serum insulin levels, improve the effect of type ii diabetes rat insulin opposing, point out Chinese patent drugs for treatment diabetes of the present invention to have multinomial regulating action.See Table 2,3,4,5,6.
The influence of table 2. pair NIDDM rat body weight
The group Mus is counted body weight (g)
Normal group 8 265.00 ± 15.96
NIDDM organizes 9 308.00 ± 18.49
*
Chinese drug-treated group 9 277.50 ± 18.95
△ △
Glipizide group 8 283.22 ± 19.09
△
Annotate: with the normal group ratio
*P＜0.01; With NIDDM group ratio
△P＜0.05,
△ △P＜0.01
The influence of table 3. pair NIDDM rat glucose tolerance
Group n blood glucose value (mmol/L)
0 30 60 120
Normal group 8 6.26 ± 1.58 10.50 ± 1.36 8.16 ± 2.37 6.85 ± 2.42
NIDDM organizes 9 7.27 ± 1.42 17.24 ± 2.63
* *14.2 ± 3.68
*10.2 ± 2.37
* ▲
Chinese drug-treated group 9 6.83 ± 1.86 14.22 ± 1.58
* * △ △11.0 ± 1.52
* △8.03 ± 1.24
△
Glipizide group 8 6.58 ± 2.45 13.22 ± 2.74
* △ △10.53 ± 3.39
△7.89 ± 1.56
△
Annotate: compare with normal group,
*P＜0.05,
*P＜0.01,
* *P＜0.001; Compare with the NIDDM group,
△P＜0.05,
△ △P＜0.01;
At once compare with this group
▲P＜0.05.
The influence of table 4. pair NIDDM rat blood serum insulin
Group n insulin (μ IU/mL)
Normal group 8 22.73 ± 2.22
NIDDM organizes 9 27.13 ± 2.38
*
Chinese drug-treated group 9 24.88 ± 1.62
* △
Glipizide group 8 24.96 ± 1.23
* △
Annotate: compare * P＜0.05, * * P＜0.01 with normal group; Compare with the NIDDM group
△P＜0.05
The influence of table 5. pair NIDDM rat blood serum triglyceride, cholesterol
Group n triglyceride (mmol/L) cholesterol (mmol/L)
Normal group 8 1.19 ± 0.25 2.74 ± 0.45
NIDDM organizes 9 2.48 ± 0.30
* *5.58 ± 0.33
* *
Chinese drug-treated group 9 1.61 ± 0.27
* △ △ △3.78 ± 0.24
* * △ △ △
Glipizide group 8 2.52 ± 0.33
* *5.70 ± 0.38
* *
Annotate: compare with normal group,
*P＜0.01,
* *P＜0.001; Compare with the NIDDM group
△ △ △P＜0.001
The influence of table 6. pair NIDDM rat serum viscosity
Group n whole blood viscosity plasma viscosity reduced viscosity
192S
-1 3.84S
-1
Normal group 8 3.65 ± 0.18 7.74 ± 1.11 1.56 ± 0.09 0.19 ± 0.03
NIDDM organizes 9 3.71 ± 0.37 7.46 ± 1.64 1.65 ± 0.08*, 0.21 ± 0.02*
Chinese drug-treated group 9 3.87 ± 0.36 5.83 ± 0.46
△1.43 ± 0.06
△0.14 ± 0.02
△ △
Glipizide group 8 4.05 ± 0.42 6.13 ± 0.81 1.54 ± 0.08 0.14 ± 0.01
△ △
Annotate: compare with normal group,
*P＜0.05; Compare with the NIDDM group
△P＜0.05
△ △P＜0.01
The specific embodiment
Below in conjunction with embodiment preparation method of the present invention is described further, following each embodiment only is used to the present invention is described but not limitation of the present invention.
Embodiment 1
Take by weighing total raw material 1000 grams by following proportioning:
Folium Mori 26～49%, Folium Nelumbinis 16～48%, Radix Salviae Miltiorrhizae 25～42%.
Take by weighing Folium Mori and add 10 times of amounts of water, soaked 20 minutes, supersound process is carried out under normal pressure, 40-60 ℃ of control ultrasound wave temperature, and ultrasonic time 30 minutes, double.Extracting solution is concentrated into certain volume, the centrifugal precipitation of removing, supernatant is walked post, and chromatographic column is filled with AB-8 type macroporous adsorbent resin wet method, is washed till eluent with distilled water and adds till 95% ethanol do not have a precipitation in macroporous adsorptive resins, again eluent is concentrated, filtrate concentrates the back and adds 95% ethanol and make and contain the alcohol amount and reach 80% concentration, leaves standstill the back sucking filtration, and precipitation is respectively given a baby a bath on the third day after its birth inferior with dehydrated alcohol, acetone, 60 ℃ of cold drying obtain amorphous powder.Take by weighing Folium Nelumbinis, be cut into filament, solubilization dosage 10-20 doubly soaked 30 minutes, and with ethanol or acid extraction, the time is 2 hours twice.Be concentrated into certain volume, ethanol extract is admixed suitable resin, volatilizes ethanol, the resin that is mixed with sample is added on the macroporous adsorptive resins of filling in advance; Acid water extracting liquid is transferred pH to 9～11 through 0.5% sodium hydroxide solution, directly upper prop.Wash decontamination earlier with water, reuse ethanol-water elution, decompression recycling ethanol, volatilize Folium Nelumbinis extract.Take by weighing Radix Salviae Miltiorrhizae, chopping, boiling water boils to be carried, and extracting solution washes decontamination through concentrating after-filtration with water by macroporous resin adsorption, water-ethanol-water elution again, the reclaim under reduced pressure eluent, drying, Radix Salviae Miltiorrhizae extract.After getting three kinds of extracts of above-mentioned Folium Mori, Folium Nelumbinis, Radix Salviae Miltiorrhizae and mixing routinely drug formulation process make Chinese patent medicine of the present invention.
Embodiment 2
Get Folium Mori 27%, Folium Nelumbinis 38%, Radix Salviae Miltiorrhizae 35%, the preparation technology of shining embodiment 1 makes Chinese patent medicine of the present invention.
Embodiment 3
Get Folium Mori 40%, Folium Nelumbinis 29%, Radix Salviae Miltiorrhizae 31%, the preparation technology of shining embodiment 1 makes Chinese patent medicine of the present invention.
Embodiment 4
Get Folium Mori 32%, Folium Nelumbinis 32%, Radix Salviae Miltiorrhizae 36%, the preparation technology of shining embodiment 1 makes Chinese patent medicine of the present invention.
Embodiment 5
Get Folium Mori 38.5%, Folium Nelumbinis 30.8%, Radix Salviae Miltiorrhizae 30.7%, the preparation technology of shining embodiment 1 makes Chinese patent medicine of the present invention.
Claims (5)
1. Chinese patent medicine for the treatment of diabetes is characterized in that it is to be made up of following component by weight percentage:
Folium Mori 26～49%, Folium Nelumbinis 16～48%, Radix Salviae Miltiorrhizae 25～42%, more than the consumption sum of each component be 100%.
2. the Chinese patent medicine of treatment diabetes according to claim 1 is characterized in that described each components contents is:
Folium Mori 32～40%, Folium Nelumbinis 24～32%, Radix Salviae Miltiorrhizae 28～36%.
3. the Chinese patent medicine of treatment diabetes according to claim 2 is characterized in that described each components contents is:
Folium Mori 38.5%, Folium Nelumbinis 30.8%, Radix Salviae Miltiorrhizae 30.7%.
4. the preparation method of treatment diabetes Chinese patent medicine preparation is characterized in that it comprises the following steps:
(1) Folium Mori are soaked, adopt ultrasonic extraction method and its liquid is concentrated, the centrifugal precipitation of removing, supernatant is walked post, is washed till eluent with distilled water and adds till ethanol do not have a precipitation, eluent is concentrated, filtrate adds ethanol after concentrating again, leaves standstill the back sucking filtration, and precipitation is respectively washed for several times with dehydrated alcohol, acetone, drying obtains Folium Mori extract.
(2) Folium Nelumbinis is cut into filament, add ethanol or sour water and soak, adopt heating reflux method to extract its concentrated solution, ethanol extract is admixed suitable resin, volatilize ethanol, resin is added on the macroporous adsorptive resins, and acid water extracting liquid is direct upper prop after the sodium hydroxide solution modulation, washes decontamination with water, reuse alcohol-water eluting, decompression recycling ethanol volatilizes, and gets Folium Nelumbinis extract.
(3) Radix Salviae Miltiorrhizae chopping, boiling water boils to be carried, extracting solution washes decontamination through concentrating after-filtration with water by macroporous resin adsorption, water-ethanol-water elution again, the reclaim under reduced pressure eluent, drying, Radix Salviae Miltiorrhizae extract.
(4) get three kinds of extracts of above-mentioned Folium Mori, Folium Nelumbinis, Radix Salviae Miltiorrhizae and mix after routinely drug formulation process make Chinese patent medicine of the present invention.
5. according to the Chinese patent medicine of claim 1,2 or 3 described treatment diabetes, the medicament that it is characterized in that gained is a said dosage form on any pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310106954 CN1251706C (en) | 2003-11-07 | 2003-11-07 | Prepared traditional Chinese medicine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310106954 CN1251706C (en) | 2003-11-07 | 2003-11-07 | Prepared traditional Chinese medicine for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1541687A true CN1541687A (en) | 2004-11-03 |
| CN1251706C CN1251706C (en) | 2006-04-19 |
Family
ID=34334294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310106954 Expired - Fee Related CN1251706C (en) | 2003-11-07 | 2003-11-07 | Prepared traditional Chinese medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1251706C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106552088A (en) * | 2017-01-18 | 2017-04-05 | 南京中医药大学 | Chinese medicine composition effective site with treatment diabetic nephropathy and its preparation method and application |
-
2003
- 2003-11-07 CN CN 200310106954 patent/CN1251706C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106552088A (en) * | 2017-01-18 | 2017-04-05 | 南京中医药大学 | Chinese medicine composition effective site with treatment diabetic nephropathy and its preparation method and application |
| CN106552088B (en) * | 2017-01-18 | 2019-10-01 | 南京中医药大学 | Chinese medicine composition active component and its preparation method and application with treatment diabetic nephropathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1251706C (en) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1053826C (en) | Tonic hypoglycemic capsule and preparing process thereof | |
| CN1876074A (en) | A constipation-treating medicament and preparation method thereof | |
| CN1205974C (en) | Thirty-six ingredients capsule for treating diabetes | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1895462A (en) | Nankang soft capsule for treating prostatitis | |
| CN1199630A (en) | Making method of medicinal vinegar bean for curing diabetes | |
| CN1251706C (en) | Prepared traditional Chinese medicine for treating diabetes | |
| CN1264543C (en) | Medicine for treating baby and child diarrhea and its preparation method | |
| CN1201768C (en) | Medication for treating diabetic retinopathy and its preparing method | |
| CN1051468C (en) | Capsule for curing rheumatism | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1272054C (en) | Medicine for treating diabetes and its preparing process | |
| CN1289111C (en) | Medicine for lowering blood lipid and softening blood vessel and its preparing method | |
| CN101036692A (en) | Application of radix codonopsis and radix astragali in the preparing of medicine for curing diabetes mellitus | |
| CN1265805C (en) | Chinese medicine oral preparation for lonering blood sugar and its preparation method | |
| CN101167953B (en) | Traditional Chinese-medicinal capsule for comprehensive treating diabetes and its producing process | |
| CN1274353C (en) | Medication for curing children's infantile malnutrition and preparation method | |
| CN102335362A (en) | Traditional Chinese medicine for treating insulin resistance of type 2 diabetes | |
| CN101485845A (en) | Chinese medicine for treating diabetes | |
| CN1310669C (en) | Medicine composition for treating chronic hepatitis and its prepn | |
| CN1772257A (en) | Fatty liver treating notoginseng prepn and its prepn process | |
| CN1223360C (en) | Chinese medicine for treating chest paralysis | |
| CN1857599A (en) | Medicine for lowering blood sugar, blood fat and blood pressure, raising blood flow rate and raising immunity and its preparing method | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN1076622C (en) | Chinese medicine for curing nephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060419 Termination date: 20171107 |